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a  b  s  t  r  a  c  t
MDMA  (“ecstasy”)  is  widely  used  as  a  recreational  drug,  although  there  has  been  some  debate  about
its neurotoxic  effects  in humans.  However,  most  studies  have  investigated  subjects  with  heavy  use  pat-
terns, and the  effects  of transient  MDMA  use  are  unclear.  In  this  review,  we  therefore  focus  on  subjects
with moderate  use patterns,  in  order to  assess  the  evidence  for  harmful  effects.  We  searched  for  studies
applying  neuroimaging  techniques  in  man.  Studies  were  included  if they  provided  at  least  one  group  with
an average  of  <50  lifetime  episodes  of  ecstasy  use or an  average  lifetime  consumption  of <100  ecstasy
tablets.  All  studies  published  before  July 2015  were  included.  Of  the  250  studies  identiﬁed  in  the  database
search,  19 were  included.
There  is no convincing  evidence  that  moderate  MDMA  use  is  associated  with  structural  or  functional
,4-Methylenedioxymethamphetamine
euroimaging
RI
hronic effects
dverse effects
brain  alterations  in  neuroimaging  measures.  The  lack  of  signiﬁcant  results  was  associated  with  high
methodological  heterogeneity  in terms  of  dosages  and  co-consumption  of other  drugs,  low  quality  of
studies and  small  sample  sizes.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).eurotoxicity
oderate use
ontents
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. Introduction
MDMA  (3,4-methylenedioxymethamphetamine) is the most
ommon psychoactive component of illicit drugs sold as “ecstasy”.
ike other amphetamines, MDMA  inﬂuences the dopamine and
orepinephrine systems, but also shows strong serotonergic effects
Liechti and Vollenweider, 2001). Because of this serotonergic
omponent, MDMA  exhibits some mental effects that differ qual-
tatively from other amphetamine-type stimulants (Schmid et al.,
014, 2015) and for this reason MDMA  has been classiﬁed as an
entactogen” (Nichols, 1986). This term can be translated as “pro-
ucing a touch within”, which describes a state of consciousness
haracterised by increased openness, positive mood and calmness
Dumont and Verkes, 2006). MDMA  was ﬁrst mentioned in a patent
f the German pharmaceutical company Merck in 1912, but was
ot widely known until its rise as a recreational drug in the 1980s.
oday, MDMA  is one of the most commonly used illicit drugs, espe-
ially in Oceania, North America and Europe, where prevalences of
etween 0.5 and 2.9% have been reported (UNODC, 2014). MDMA  is
urrently often sold as crystals of relatively high purity (EMCDDA,
015).
For over 20 years, there has been an ongoing debate about pos-
ible neurocognitive alterations in MDMA  users and concerns that
DMA  may  be neurotoxic – especially to serotonergic neurons
Parrott, 2013). Many neuroimaging studies in MDMA consumers
ave been published. Most of these studies investigated samples
ith heavy use patterns, reﬂected in cumulative lifetime doses
f hundreds or even thousands of consumed units and typically
o-use of many other substances. However, use of MDMA  is an
ncidental and transient phenomenon for most consumers and
hese studies therefore do not describe this large cohort appropri-
tely (von Sydow et al., 2002; Webb et al., 1996). Only 15% of all
DMA  users show considerable or heavy use patterns and approx-
mately 80% of occasional users stop their use of MDMA  and related
rugs in their twenties (von Sydow et al., 2002). Moreover, there
s increasing evidence that MDMA  may  be useful in psychother-
py, especially in the treatment of posttraumatic stress disorder
Mithoefer et al., 2011; Oehen et al., 2013). In this approach, MDMA
s used as an additive in a psychotherapeutic setting and its admin-
stration is restricted to a few, typically 2–5, therapeutic sessions.
iven the controversial debates surrounding MDMA,  this approach,
nsurprisingly, has been questioned (Parrott, 2014). Therefore,
esults on moderate MDMA  use might also be informative for this
ebate.
In the present study, we systematically reviewed structural,
unctional and neurochemical brain imaging studies in moderate
DMA  users, as deﬁned by an average cumulative lifetime use of
50 lifetime episodes of ecstasy use or a lifetime consumption of
100 ecstasy tablets.
. Methods
To ensure high quality reporting, we adhered to the recommen-
ation for systematic reviews of the PRISMA statement (Moher
t al., 2015).
.1. Search strategy
Electronic search was performed using the PubMed database.
he following search term was used: (mdma  OR ecstasy OR 3,4-
ethylenedioxymethamphetamine) AND (mri OR fmri OR pet OR
pect OR imaging OR neuroimaging). All studies published before
uly 2015 were included, without any language restriction. Addi-
ionally, the reference lists of all included studies identiﬁed in the
atabase search were manually screened for relevant studies.havioral Reviews 62 (2016) 21–34
2.2. Selection criteria and study selection
Inclusion criteria were (1) original publication in a peer-
reviewed journal, (2) observational or interventional study design,
(3) application of structural, functional or neurochemical neu-
roimaging techniques, (4) investigation of non-acute effects of
MDMA  on the human brain, (5) inclusion of at least one group
with an average of <50 lifetime episodes of ecstasy use or an
average lifetime consumption of <100 ecstasy tablets. After inspec-
tion for duplicates, the titles and abstracts of all records were
reviewed. Publications that clearly did not meet inclusion crite-
ria were excluded. The decision for inclusion or exclusion of the
remaining publications was made on the basis of a review of the
full texts. The whole process was  conducted by two reviewers (FM,
MS)  independently. In case of disagreement, reviewers discussed
their reasons for initial inclusion and exclusion. If consensus was
not reached, a third reviewer (CL) was included.
2.3. Recorded variables, data extraction and analysis
The recorded variables for each article included in the review
were: centre where the study was performed, authors and year
of publication, study design, imaging method, number of sub-
jects, number of subjects overlapping with other included studies,
age, gender distribution, cumulative lifetime exposure to ecstasy
(tablets, episodes, dosage in mg), usual MDMA  dose per occasion,
maximum MDMA  dose per occasion, age at onset of MDMA use,
time since last MDMA  use, duration of MDMA  use, control group
matched for use of other drugs, required abstinence from alcohol,
nicotine, cannabis and other (illicit) drugs, domains tested, regions
analysed, statistical thresholds and principle ﬁndings (user group
vs. controls and within-group results). When data were missing but
computation based on the original publication was  possible, the
missing values were calculated and included in the review. If nec-
essary, units were transformed. If overlaps between subjects were
suspected but the original publications did not contain information
on that topic, we contacted the authors and included the obtained
data in the review.
2.4. Standardisation of data on lifetime ecstasy use
The data on lifetime ecstasy use provided in the included stud-
ies were heterogeneous (tablets, episodes, dosage in mg). In order
to obtain comparable results, we performed an additional search
for articles providing information about the content of MDMA  in
ecstasy tablets. Additionally, we calculated the mean number of
tablets consumed per episode, on the basis of the data provided in
the studies included in this review.
Three studies, with a total sample of 1149 tablets, were identi-
ﬁed between 1991 and 2006 (Table 1). Tablets sold as ecstasy had
a weighted mean of 76 mg  per tablet.
To convert data from studies which only provided lifetime use
in terms of sessions of ecstasy use, we  also calculated the weighted
mean of tablets consumed during a single occasion. We  thereby
used data (n = 83) from studies included in this review, but due
to overlaps, only four such studies were suitable (Daumann et al.,
2003b, 2011; Erritzoe et al., 2011; Reneman et al., 2001). A weighted
mean of 1.3 tablets per occasion was calculated.
3. Results
3.1. Identiﬁed studiesOf 250 publications found in the PubMed database and one arti-
cle identiﬁed in the reference lists, 19 articles were included in
this review. 165 publications clearly did not meet the inclusion
F. Mueller et al. / Neuroscience and Biobehavioral Reviews 62 (2016) 21–34 23
Table  1
Content of MDMA per tablet.
Authors Country Period Origin of samples n Mean content of MDMA  per tablet (mg)
Wood et al. (2011) United Kingdom 2006 Sequestration 101 58.7
Cole et al. (2002) United Kingdom 1991–2001 Sequestration 865 79.1
Mc  Fadden et al. (2006) Ireland 2002–2003 Sequestration 183 69.2
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F
iriteria (e.g. animal models, case reports, studies without neu-
oimaging, comments) and were thus excluded. Of the remaining
5 publications, 53 studies were excluded because inclusion crite-
ia on lifetime consumption of ecstasy were not met; nine studies
ere excluded because only acute effects of MDMA  were exam-
ned; three studies were excluded because lifetime consumption
as reported as range (and not as average) and one study was
xcluded because neuroimaging results had already been reported
n another included study. A ﬂowchart of the selection procedure,
ith the included and excluded studies, is shown in Fig. 1.
Of the total of 19 included articles, ten used fMRI during dif-
erent tasks, four were neurochemical imaging studies (three PET,
ne SPECT), one used SPECT as well as structural MRI  (sMRI; de
in  et al., 2008) and ﬁve used other techniques. Details are shown
n Table 2. All studies were published between 2001 and 2014.
xcept for four studies, most surveys were performed by three cen-
res (Aachen/Cologne, Amsterdam/Utrecht, Nashville) and showed
ome overlaps between subjects (see Table 2). Five studies inves-
igated the use of amphetamine-type stimulants and thus did not
ocus on MDMA  exclusively (Becker et al., 2013; Daumann et al.,
011; Koester et al., 2012, 2013; Mackey et al., 2014). Due to
Fig. 1. Selection 
igure is based on the template of the PRISMA ﬂow diagram from www.prisma-statem
ncluded  study, (Cowan et al., 2007; Cowan et al., 2006; Cowan et al., 2003); no data provSum: 1149 Weighted mean: 75.7
our limitation for the cumulative lifetime doses of MDMA, we
only included subgroups in some studies (Daumann et al., 2003a;
Koester et al., 2013; Daumann et al., 2011; Koester et al., 2012;
Erritzoe et al., 2011).
All included studies used an observational design, which was
mostly retrospective (15/19). Three prospective studies from the
Amsterdam/Utrecht centre investigated a population with no
use of ecstasy at baseline but a high probability of starting to
use ecstasy in the future (De Win  et al., 2005). Another study
prospectively investigated a sample with “ﬁrst but limited expe-
rience” with amphetamine-type stimulants (Becker et al., 2013).
All but two  studies (de Win  et al., 2007; Moreno-Lopez et al.,
2012) included control groups, that were matched for age, with
one exception (de Win  et al., 2008), and gender, also with one
exception (Roberts et al., 2009) case; user and control groups were
matched for education or IQ in all three cases (Daumann et al.,
2011; Koester et al., 2012, 2013); two studies reported no data
on level of education (Di Iorio et al., 2012; Reneman et al., 2001).
Most studies did not provide a control group that was matched
for use of other drugs (see Table 4). All but one study (Moreno-
Lopez et al., 2012) reported some kind of control of abstinence
procedure.
ent.org.1 (de Win  et al., 2004): Neuroimaging results already reported in another
ided about average lifetime consumption of MDMA.
24 F. Mueller et al. / Neuroscience and Biobehavioral Reviews 62 (2016) 21–34
Table 2
Characteristics of all included studies.
Centre Authors and year
of publication
Study
design
Modality n subjects
overlapping withn
User group Control group
p r n m/f  age n m/f  age
Aachen/Cologne
Daumann et al. (2003a)1 X fMRI 72, 83,4 11 8/3 23.3 11 8/3 25.6
Daumann et al.
(2003b)2 X fMRI 7
1
8 4/4 25.3
8 4/4 25.648 4/4 26.4
Daumann et al. (2011)3 X sMRI 81, 424, 155, 186 42 30/12 23.6 16 9/7 26.3
Koester et al. (2012)4 X sMRI 81,423, 155, 186 42 30/12 23.6 16 9/7 26.3
Becker et al. (2013)5 X fMRI 153,4 17 14/3 22.73 12 11/1 23.43
Koester et al. (2013)6 X fMRI 183,4 18 12/6 22.9 15 9/6 26.5
Amsterdam/Utrecht
Reneman et al. (2001)7 X SPECT 158 15 9/6 24.41 15 7/8 26.11
de Win  et al. (2007)8 X sMRI 3011 30 12/18 22.52 – – –
Jager et al. (2007)9 X fMRI 2511 25 9/16 22.82 24 8/16 23.02
de Win  et al. (2008)10 X sMRI, SPECT 309, 2510 59 25/34 23.02 56 23/33 23.12
Copenhagen Erritzoe et al. (2011)11 X PET – 10 9/1 23.3 21 17/4 23.8
Granada Moreno-Lopez et al. (2012)12 X PET – 49 41/8 32.7 – – –
Nashville
Karageorgiou et al. (2009)13 X fMRI 514,1416, 1017 14 10/4 26.0 10 5/5 22.9
Bauernfeind et al. (2011)14 X fMRI 513,16, 1017 20 n/p n/p 20 n/p n/p
Di Iorio et al. (2012)15 X PET – 14 0/14 21.6 10 0/10 21.6
Salomon et al. (2012)16 X fMRI 1413, 514,1017 14 10/4 26.0 10 5/5 22.9
Watkins et al. (2013)17 X fMRI 1013,16,1014 23 17/6 24.6 11 5/6 22.4
New  Haven Jacobsen et al. (2004)18 X fMRI – 6 2/4 17.3 6 2/4 17.1
San  Diego Mackey et al. (2014)19 X sMRI – 165 101/64 20.9 46 21/25 21.0
1Calculated weighted mean, 2Age at follow up, 3 Age at baseline.
Table 3
Characteristics of MDMA  use.
Centre Authors and year
of publication
Data provided about lifetime doses of ecstasy in original publication Calculated
lifetime
dose (mg)Cumulative lifetime dose Usual dose
per occasion
(tablets)
Maximum dose
per occasion
(tablets)
Age at
onset of
use
Time since
last use
(days)
Duration of
use (days)
Tablets Episodes mg
Aachen/Cologne
Daumann et al.
(2003a)
27.36 n/p n/p 1.57 n/p 20.2 330.1 486.0 2071.15
Daumann et al.
(2003b)
74.50 n/p n/p 1.66 n/p 22.8 23.0 1028.7 5639.65
56.25 n/p n/p 1.44 n/p 19.0 62.4 552.9 4258.13
Daumann et al.
(2011)
2.89 n/p n/p 1.02 1.58 20.4 670.0 n/p 218.77
Koester et al. (2012) 2.89 n/p n/p 1.02 1.58 20.4 670.0 n/p 218.77
Becker et al. (2013) 9.503 n/p n/p 1.36 2.02 20.6 86.3 n/p 719.15
Koester et al. (2013) 2.65 n/p n/p 1.18 n/p n/p 930.7 n/p 200.61
Amsterdam/Utrecht
Reneman et al.
(2001)
28.6 n/p n/p 1.4 n/p n/p 108 1492.4 2165.02
de Win  et al. (2007) 1.8 n/p n/p n/p n/p n/p 53.9 14.7 136.26
Jager et al. (2007) 2.0 n/p n/p n/p n/p n/p 77.7 36 151.40
de Win  et al. (2008) 6.0 n/p n/p n/p n/p n/p 130.9 142.8 454.20
Copenhagen Erritzoe et al.
(2011)
60 18 n/p 1.8 n/p 18.2 122 1713 4542.00
Granada Moreno-Lopez et al.
(2012)
13.41 n/p n/p n/p n/p n/p 230.64 511 1015.14
Nashville
Karageorgiou et al.
(2009)
n/p 29.6 2365.2 n/p n/p n/p 669.4 n/p 2912.94
Bauernfeind et al.
(2011)
n/p 33.25 2692.38 n/p n/p n/p 478.0 n/p 3272.13
Di Iorio et al. (2012) n/p 13.5 1400.00 n/p n/p n/p 689.5 n/p 1328.54
Salomon et al.
(2012)
n/p 29.6 2365.2 n/p n/p n/p 669.4 n/p 2912.94
Watkins et al.
(2013)
n/p 16.0 1250.0 n/p n/p n/p 476.0 n/p 1574.56
New  Haven Jacobsen et al.
(2004)
n/p 10 n/p n/p n/p 15.8 n/p 547.51 984.10
San  Diego Mackey et al.
(2014)
n/p 3.1 n/p n/p n/p 19.0 n/p 675.3 305.07
n/p = not provided.
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Table 4
Co-consumption of other drugs and times of abstinence from other drugs.
Centre Authors and year
of publication
Reported signiﬁcant differences
between MDMA group and control
or between baseline and follow-up
in use of other illicit drugs
Reported signiﬁcant
differences in use of
alcohol and nicotine
Calculated signiﬁcant
differences in lifetime
dose of other drugs
(unpaired t-test, p < 0.05)
Required abstinence from different drugs (days)
Alcohol Nicotine Cannabis Other drugs
Aachen/Cologne
Daumann et al. (2003a) n/p1 n/p Not enough data provided 7 n/p 0 7
Daumann et al. (2003b) none n/p Not enough data provided n/p n/p 0 7
Daumann et al. (2011) n/p2* n/p Cannabis, amphetamines5,6 7 n/p 0 7
Daumann et al. (2011) n/p2 n/p Cannabis, amphetamines5,6 7 n/p 1 7
Koester et al. (2012) Amphetamines* none* – 7 n/p 1 7
Becker et al. (2013) n/p2* n/p Cannabis, amphetamines5.6 7 n/p 1 7
Amsterdam/Utrecht
Koester et al. (2013) n/p3 none Not enough data provided n/p n/p 21 21
Reneman et al. (2001) Cocaine* none – n/p n/p 14 14
de Win  et al. (2007) none none – 7 0 14 14
Jager et al. (2007) Cannabis,
amphetamine,
cocaine*
Alcohol* – 7 n/p 14 14
Copenhagen de Win  et al. (2008) n/p4* none Not enough data provided n/p n/p 7 7
Granada Erritzoe et al. (2011) n/a (no control
group)*
n/a (no control group)* – 15 0 15 15
Nashville
Moreno-Lopez et al. (2012) Cocaine* none (nicotine n/p)* – 2 n/p 2 14
Karageorgiou et al. (2009) n/p* n/p* Not enough data provided 2 n/p 14 14
Bauernfeind et al. (2011) Psilocybin* none* – 3 n/p 14 14
Di Iorio et al. (2012) Cocaine n/p Not enough data provided 2 n/p 2 14
Salomon et al. (2012) Cannabis, cocaine,
LSD, psilocybin,
opium*
none* – 2 n/p 14 14
New  Haven Watkins et al. (2013) n/p none Not enough data provided n/p n/p n/p n/p
San  Diego Jacobsen et al. (2004) Cannabis* Nicotine, alcohol* – n/p n/p 3 3
1 No previous or current history of regular drug use or regular heavy alcohol use in control group, 2 Drug-naïve control group, 3 MDMA users reported more amphetamine and cocaine use than controls, 4 Control group < 15
lifetime  episodes of cannabis use and no history of other illicit drugs, 5 Studies investigated amphetamine-type stimulants and not MDMA  exclusively, 6 No data for alcohol and nicotine provided, n/a = not applicable, n/p = not
provided,  *Accounting for at least one of these potential confounders.
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rom drugs, mostly by urine drug screening. We  have appended
ummary tables of all included studies to assist the reader to form
n independent view of the core results (Tables 2–4).
.2. Functional imaging studies
Ten studies used fMRI during different tasks (four working
emory, two associative memory, one decision making, two selec-
ive attention, two motor function, one visual stimulation, one
emantic memory). For details see Table 5. Of the studies reporting
esults of task performance, all (Daumann et al., 2003a,b; Becker
t al., 2013; Jager et al., 2007; Karageorgiou et al., 2009; Watkins
t al., 2013) but two (Jacobsen et al., 2004; Koester et al., 2013)
eported no signiﬁcant differences between users and controls.
Daumann et al. performed two fMRI studies investigating work-
ng memory via n-back tasks with three levels of difﬁculty (0-,
-, 2-back task) (Daumann et al., 2003a). The control group was
rug-naïve, while the MDMA  user group showed use of cannabis
nd amphetamine as well, but no clear data was provided about
he extent of use of these drugs. No signiﬁcant differences were
eported for a restrictive statistical threshold in terms of the BOLD
ignal. For a liberal threshold, increases in activation in the right
arietal cortex (1-back, 2-back) and the left parietal cortex (2-back)
ere observed. In order to address the limitations from the use of
ther drugs in the MDMA  group, the authors compared a polydrug
ser and a drug-naïve control group using the same task in their
econd study (Daumann et al., 2003b). “Pure use” of MDMA  was
eﬁned as no use of other substances more than “once per month or
ore frequently over 6 months within the last two years”. The dura-
ion of abstinence was considerably shorter than in the ﬁrst study.
olydrug users showed no signiﬁcant differences compared with
ontrols in the fMRI results. Compared with controls, pure MDMA
sers showed decreased activation in the inferior temporal region
1-back) and angular gyrus (1-back, 2-back) and, compared with
he polydrug user group, decreased activation in the striate cortex
1-back) and the angular gyrus (2-back) and increased activation in
he premotor cortex (1-back).
Jacobsen et al. used an auditory n-back task (1-, 2-back) to exam-
ne working memory, and a selective, divided attention paradigm
binaural and dichotic verbal stimuli) in adolescents during fMRI
Jacobsen et al., 2004). The study focused exclusively on the hip-
ocampus. An additional binaural 3-back task was tested in three
ontrols and all MDMA  users. Groups were matched for use of nico-
ine and alcohol, but only a few details were reported of illicit drug
se histories. One MDMA  user was reported to have consumed
ocaine as well and all but one participant in the control group had
 history of cannabis use of unclear extent. Compared with con-
rols, the MDMA  user group showed less deactivation in the left
ippocampus during the dichotic 2-back condition and this was
till signiﬁcant after removal of two subjects with a positive urine
creen for cannabis (one MDMA  user, one control). The binaural
-back task was used for correlation with parameters of MDMA
se. A negative correlation was observed between activation of the
eft hippocampus and time of abstinence, which was  most pro-
ounced during the binaural 3-back task (r = −0.05); no correlation
as found for cumulative lifetime dose or onset of use.
Jager et al. tested three paradigms during fMRI acquisition
Jager et al., 2007). In this prospective design, none of the par-
icipants had used MDMA  at baseline and they only exhibited a
mall exposure at follow-up. Subjects were tested for working
emory (item-recognition task), associative memory (pictorialssociative memory task) and selective attention (visuo-auditory
elective attention). The control group was matched for use of all
rugs that were taken into account (alcohol, nicotine, cannabis,
ther amphetamines, cocaine). The whole brain as well as the ROIhavioral Reviews 62 (2016) 21–34
analysis showed no signiﬁcant differences between the user and
the control group for any of the paradigms.
Becker et al. prospectively investigated associative memory in a
sample of amphetamine-type stimulants users with limited experi-
ence of MDMA  and/or other amphetamines (Becker et al., 2013). At
the whole brain level, no signiﬁcant differences were reported. An
ROI analysis of the hippocampus and the parahippocampus yielded
decreased encoding-related activity in the left parahippocampal
gyrus, which was negatively correlated with interim use of MDMA,
but not cannabis or other amphetamines. The authors noted that
differences in hippocampal activity between interim abstinent
subjects and subjects who  continued use of amphetamine-type
stimulants were already present at baseline. They discuss differ-
ent durations of abstinence as an explanation for this ﬁnding and
notice that the observed results in the parahippocampal gyrus were
also driven by a relative increase in activity in the interim absti-
nent users, which might be due to recovery during this time of
abstinence.
Koester et al. examined decision-making in amphetamine-type
stimulants users (Koester et al., 2013). The control group had no
experience with any illicit drugs, including cannabis. No attempt
was made to disentangle use of MDMA  and other amphetamines.
Subjects had to choose between control gambles with a 50% chance
of losing or winning a small amount of money and experimen-
tal gambles with a low or a high chance of losing or winning.
Drug-naïve controls chose fewer experimental gambles than the
amphetamine-type stimulants group. With the FMRIB’s Local Anal-
ysis of Mixed Effects, no signiﬁcant differences were observed;
however, with ordinary least squares, they observed an increased
BOLD signal in the right parietal lobe during high probabilities of
winning.
Watkins et al. tested semantic memory in a cohort that consisted
mostly of subjects already examined in the ﬁrst two fMRI stud-
ies from the same centre (Bauernfeind et al., 2011; Karageorgiou
et al., 2009). The MDMA  user group showed signiﬁcantly more con-
sumption of a variety of other drugs (cannabis, cocaine, opium,
sedatives, LSD, psilocybin). During semantic encoding, the user
group showed greater activation in the left precuneus and the right
superior parietal lobule, whereas no differences were observed dur-
ing semantic recognition. Activation in the right superior parietal
lobe was  positively correlated with lifetime ecstasy use (Spear-
man’s rho, rS = 0.43, p = 0.042). No signiﬁcant correlation was found
between lifetime use of other drugs and activation in the right
superior parietal lobule or the left precuneus.
Karageorgiou et al. tested motor function with fMRI using a
motor tapping task (1-, 2-, 4-tap task) (Karageorgiou et al., 2009).
The user group showed a signiﬁcantly higher use of cocaine than
controls. The ROI analysis yielded an increased BOLD signal and
an increase in percent activated voxels in the right supplemen-
tary motor area during the tap-4 condition in the MDMA  user
group compared with controls. No dose dependent effect was
observed. For the within-group comparison, a positive correla-
tion was described between the amount of MDMA  use and the
BOLD signal increase in the right putamen and the right pal-
lidum, as well as with the spatial extent of activation in the right
precentral cortex and the left thalamus. No differences in the
right supplementary motor area were observed in the within-
group comparison and no correlation was  found between lifetime
episodes of alcohol, cannabis, cocaine and methamphetamine use
and BOLD signal. For the tap-4 condition, a signiﬁcant association
was seen between alcohol use and percentage of activated vox-
els in the left postcentral and left precentral cortex. No association
was found for other drugs (cannabis, cocaine, methamphetamine).
Salomon et al. reanalysed the data set from Karageorgiou et al.
for intraregional coherence and functional connectivity (Salomon
et al., 2012). Reduction in intraregional thalamic coherence and
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Table 5
Included functional imaging studies: Imaging results.
Authors and year of
publication
Modality Tested domain Regions analysed Threshold Results (user group compared with
controls, if not indicated otherwise)
Daumann et al.
(2003a)
fMRI Working memory (n-back task) Whole brain p < 0.05 corrected, p < 0.01 and
p < 0.001 uncorrected,
cluster ≥ 5
0-back: No signiﬁcant differences
1-back: Right parietal cortex ↑ (p < 0.001
uncorrected)
2-back: Right and left parietal cortex ↑
(p  < 0.01, uncorrected)
Daumann et al.
(2003b)
fMRI Working memory (n-back task) Whole brain p < 0.001, uncorrected,
cluster ≥ 5
0-back: No signiﬁcant differences
1-back: Polydrug user versus control
group: No signiﬁcant differences; Pure
MDMA user vs. control group: Inferior
temporal, angular region ↓; Pure MDMA
user vs. polydrug user: striate cortex ↓,
premotor cortex ↑
2-back: Polydrug user versus control
group: No signiﬁcant differences; Pure
MDMA user versus control group: Angular
gyrus ↓; Pure MDMA user versus polydrug
user: Angular gyrus ↓
Becker
et al.
(2013)
fMRI
Associative memory (encoding and
retrieval task)
Whole brain p < 0.05, corrected (FWER),
cluster ≥ 10
No signiﬁcant differences
ROI:  Hippocampus,
parahippocampus
p < 0.05, corrected (FWER,
small volume correction),
cluster ≥ 10
Left parahippocampal gyrus: encoding
related activity ↓
Koester et al.
(2013)
fMRI Decision making
(gambling task)
Whole brain p < 0.05, corrected, cluster
Z  > 2.3
FLAME: No signiﬁcant differences
OLS: Right parietal lobe ↑ (high probability
of winning)
Jager et al. (2007) fMRI
Working memory (item-recognition
task)
Whole brain, ROI: left superior
parietal cortex, left dorsolateral
prefrontal cortex, anterior
cingulate cortex, left fusiform
gyrus
p < 0.05, corrected (FWER) No signiﬁcant differences
Selective attention (visuo-auditory
selective attention task)
Whole brain, ROI: Right inferior
frontal gyrus, left and right
auditory cortex, anterior cingulate
cortex, left precentral gyrus, left
insula, visual cortex, left inferior
frontal gyrus
Associative memory (pictorial
associative memory task)
Whole brain, ROI: Right and left
(para)hippocampal regions, right
and left dorsolateral prefrontal
cortex, right and left middle
occipital gyrus, anterior cingulate
cortex, right and left inferior
frontal gyrus
28
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Table 5 (Continued)
Authors and year of
publication
Modality Tested domain Regions analysed Threshold Results (user group compared with
controls, if not indicated otherwise)
Karageorgiou et al.
(2009)
fMRI Motor function (motor tapping task) Supplementary motor area,
precentral gyrus, caudate,
putamen, pallidum, thalamus,
postcentral gyrus
Between group contrast:
p ≤ 0.05, uncorrected,
cluster ≥ 26
Within-group contrast:
p < 0.001, uncorrected
Between group effect: Right
supplementary motor area ↑ (tap 4
condition)
Within-group dose effects: Percent BOLD
signal change: Right putamen, right
pallidum ↑, Percent activated voxels: Right
precentral cortex, right and left thalamus ↑
Bauernfeind et al.
(2011)
fMRI Visual stimulation (two-colour visual
stimulation task)
Bilateral geniculate nucleus,
bilateral BA17, bilateral BA 18
Intensity: p < 0.05, corrected,
cluster ≥ 90 voxels (Monte
Carlo simulation to generate
p < 0.05 corrected for FWER)
Extent: p < 0.001, uncorrected
Within-group dose effect: Activation in
lateral geniculate nucleus, BA 17, BA18 ↑,
spatial extent in BA 17 and 18 ↑, after
adjusting for different scanners and
stimulus delivery methods, only activation
in lateral geniculate nucleus remained
signiﬁcant
Between-group: No signiﬁcant differences
in activation and spatial extent (spatial
extent in BA17 and 18 ↑ in heavy users,
signal intensity in lateral geniculate
nucleus ↑ in low users)
Salomon et al.
(2012)
fMRI Motor function (motor tapping task);
coherence and functional connectivity
Supplementary motor area,
precentral gyrus, caudate,
putamen, pallidum, thalamus,
postcentral gyrus,
pontomesencephalic pontine
raphé region
p ≤ 0.05, corrected (Bonferroni
correction)
Intra-regional coherence: Bilateral
thalamus (low frequencies) ↓, right
thalamus (medium frequencies) ↓
Functional connectivity: Left caudate –
right thalamus, right caudate – right
postcentral gyurs, right supplementary
motor area – right precentral gyrus,
bilateral thalamus ↓
Watkins et al.
(2013)
fMRI Semantic memory (encoding and
recognition of words)
Cortex p < 0.01, cluster ≥ 276 voxels
(Monte Carlo simulation to
generate p < 0.05 corrected for
FWER)
Left precuneus, right superior parietal
lobule (semantic encoding)↑
Jacobsen et al.
(2004)
fMRI Working memory, selective and
divided attention (binaural and
dichotic verbal and binaural 3- back,
auditory 2-back task)
Hippocampus p ≤ 0.01, uncorrected,
cluster ≥ 8
Left hippocampus ↑ (dichotic 2-back
condition) (0.8)
↑ = increase, ↓ = decrease, ROI = Region of interest, FWER = family wise error rate, FLAME = FMRIB’s Local Analysis of Mixed Effects, OLS = ordinary least squares.
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Table  6
Included MRI  studies applying further techniques.
Authors and
year of
publication
Modality Tested domain Regions analysed Threshold Results (user group compared
with controls, if not indicated
otherwise)
Daumann et al.
(2011) MRI
DTI (fractional anisotropy) White matter p < 0.05, FWER corrected,
cluster-based threshold
No signiﬁcant differences
sMRI (VBM) Grey matter
Koester et al.
(2012) MRI
sMRI (VBM)
Whole brain p < 0.05, FWER corrected,
cluster-based threshold
Cortical thickness: No
signiﬁcant differences
Cortical grey matter volume:
Volume in orbitofrontal (left)
and occipital (right) regions↓
ROI: hippocampus,
thalamus, nucleus
accumbens, putamen,
nucleus caudatus, globus
pallidus
FDR No signiﬁcant differences
de Win  et al.
(2007) MRI
1H-MRS
(N-acetylaspartate, choline,
myo-inositol, creatine)
Mid-frontal, mid-occipital
grey matter, left centrum
semiovale
p < 0.05, post hoc
Bonferroni correction:
1H-MRS p < 0.006, DTI:
p  < 0.010,
rrCBV p < 0.005
p < 0.05, uncorrected: No
signiﬁcant differences
DTI (fractional anisotropy,
apparent diffusion)
Thalamus, globus pallidus,
putamen, caudate nucleus,
centrum semiovale
p < 0.05, uncorrected: FA:
centrum semiovale ↑, ADC:
thalamus ↓; Bonferroni
correction : No signiﬁcant
differences
PWI  (relative regional
blood ﬂow)
Thalamus, globus pallidus,
putamen, caudate nucleus,
dorsolateral frontal,
mid-frontal, occipital,
superior parietal, temporal
grey matter, centrum
semiovale
p < 0.05, uncorrected:
Thalamus, dorsolateral frontal
cortex, superior parietal grey
matter ↓; p < 0.005 Bonferroni
correction: dorsolateral frontal
grey matter↓
de Win  et al.
(2008) MRI
1H-MRS
(N-acetylaspartate, choline,
myo-inositol, creatine)
Mid-frontal, mid-occipital
grey matter, left
frontoparietal white matter
p < 0.05, uncorrected
p < 0.05, uncorrected
No signiﬁcant differences
DTI (fractional anisotropy,
apparent diffusion)
Thalamus, globus pallidus,
putamen, caudate
nucleus, frontoparietal
white matter
FA: thalamus, frontoparietal
white matter ↓, globus pallidus
↑; ADC: thalamus ↑
PWI  (relative regional
blood ﬂow)
Thalamus, globus pallidus,
putamen, caudate nucleus,
dorsolateral frontal,
mid-frontal, occipital,
superior parietal tempor,
temporal grey matter
Globus pallidus, putamen ↓
Mackey et al.
(2014)
MRI  sMRI (VBM) Whole brain p < 0.01, cluster-extent
correction (132 voxels)
Grey matter volume: left
ventral anterior putamen ↑,
right dorsolateral cerebellum,
right inferior parietal cortex↓
↑ , FDR
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c = increase, ↓ = decrease, cho = choline, cr = creatine, FWER = family wise error rate
nterest, DTI = diffusion tensor imaging, MRS  = magnetic resonance spectroscopy, PW
eaker interregional functional connectivity in different region-
airs were reported. The functional connectivity within-group
nalysis showed relationships between lifetime use of MDMA  and
arious region-pairs. This was not accounted for by the signiﬁcantly
igher use of cocaine in the MDMA  user group.
Bauernfeind et al. conducted an ROI analysis of visual stimula-
ion during fMRI (Bauernfeind et al., 2011). Control subjects were
ncluded but no clear data about drug use patterns in this group
ere provided. For the within-group analysis, a positive correlation
Spearman‘s Rank correlations) was reported between cumula-
ive lifetime use and the stimulus-evoked activation in the lateral
eniculate nucleus (rS = 0.59), BA 17 (rS = 0.50) and 18 (rS = 0.48),
s well as with the spatial extent of activation in BA 17 (rS = 0.59)
nd 18 (rS = 0.55). After adjusting for two different scanners and
timulus delivery methods, only the activation in the lateral genic-
late nucleus remained signiﬁcant. After inclusion of lifetime use
f other drugs, some effects were seen for use of MDMA  com-
ined with methamphetamine, but not for other drugs (alcohol,
annabis, cocaine, codeine, LSD, opium, psilocybin, sedatives). For = false discovery rate, mI  = myo-inositol, NAA = N-acetylaspartate, ROI  = Region of
rfusion weighted imaging, VBM = voxel-based morphometry.
the between-group comparison, no differences were seen in signal
intensity or spatial extent. After splitting the MDMA  group into low
and high exposure groups, a signiﬁcantly greater spatial extent of
activation was reported in BA 17 and 18 (heavy user group), with
decreased signal intensity in the lateral geniculate nucleus (low
exposure group).
3.3. Other MR imaging techniques
Five studies applied other MR  Imaging techniques. For details
see Table 6.
Daumann et al. (2011) and Koester et al. (2012) investigated the
same cohort using a VBM approach and focused on grey matter
(Daumann et al., 2011), cortical thickness/volume and subcortical
structures (Koester et al., 2012), respectively. Use of MDMA and
other amphetamines was  not differentiated in the analysis, but
summarised under “use of amphetamine-type stimulants”. No sig-
niﬁcant differences were reported, except for reductions in the
volumes of the small left orbitofrontal and right occipital regions
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Koester et al., 2012). Mackey et al. conducted a VBM whole brain
nalysis in a population with a substantially higher use of (prescrip-
ion) amphetamine-type stimulants, and of cocaine rather than
DMA  (mean 24.5/21.4 episodes vs. 3.1 episodes) (Mackey et al.,
014). The control group was not matched for nicotine, alcohol and
annabis use and, due to the design, showed no use of prescription
timulants and cocaine. The authors reported increased volume of
he left ventral anterior putamen and decreased volume of the right
orsolateral cerebellum and the right inferior parietal cortex. They
oted that including or excluding the use of MDMA  in the analy-
is did not have any substantial effect on their results. They also
ound correlations between the use of other amphetamine type
timulant/cocaine and various areas.
In two prospective studies in subjects with no use of MDMA at
aseline, De Win  et al. investigated brain metabolites by 1H-MRS,
egional relative blood ﬂow by PWI, as well as apparent diffusion
oefﬁcient and fractional anisotropy by DTI (de Win  et al., 2007,
008). The 2007 study examined a cohort soon after their ﬁrst use
f ecstasy. No control group was included and subjects showed
 signiﬁcant interim increase in cocaine use. With a liberal sta-
istical criterion (p < 0.05, uncorrected for multiple comparisons),
n increase in fractional anisotropy in the centrum semiovale, a
ecrease in apparent diffusion in the thalamus and a decrease in
egional relative blood ﬂow in the thalamus, dorsolateral frontal
nd superior parietal grey matter were reported. After correction
or multiple comparisons, only the decrease in blood ﬂow in the
orsolateral frontal grey matter remained signiﬁcant. The authors
able 7
ncluded neurochemical imaging studies.
Authors and year of
publication
Modality Tested domain Regions an
de Win  et al.
(2008)
[123I]-CIT SPECT Serotonin transporter
Whole bra
ROI: midb
temporal c
cortex, occ
Reneman et al.
(2001)
[123I]-CIT SPECT Serotonin transporter Frontal cor
cortex, par
cortex, occ
thalamus, 
Erritzoe et al.
(2011)
[18F]altanserin/
[11C]DASB PET
Serotonin transporter
and serotonin2A
receptor
Orbitofron
inferior fro
superior fr
superior te
medial inf
cortex, sen
parietal co
cortex (ser
and seroto
pallidostri
amygdala,
(serotonin
Moreno-Lopez
et al. (2012)
FDG-PET n/a Whole bra
Di Iorio et al.
(2012)
[18F]Setoperone
PET
Serotonin2A receptor Whole cor
 = increase, FWER = family wise error rate, ROI = Region of interest.havioral Reviews 62 (2016) 21–34
corrected for the parallel increase in cocaine use by excluding these
subjects in a second analysis. Except for the increase in fractional
anisotropy in the centrum semiovale, all results with the liberal cri-
terion remained unchanged, as did the result with the conservative
criterion. In their 2008 study, a larger cohort with increased use of
MDMA  was  examined. With a threshold of p < 0.05 (uncorrected),
they reported a decrease in fractional anisotropy in the thala-
mus  and the frontoparietal white matter, an increase of fractional
anisotropy in the globus pallidus, an increase in apparent diffusion
in the thalamus and a decrease in regional relative blood ﬂow in
the globus pallidus and putamen. The user group showed a signiﬁ-
cant interim increase in the use of alcohol, cannabis, amphetamine
and cocaine. However, all results remained signiﬁcant after cor-
rection for these confounders. White matter tract integrity has
been assessed by fractional anisotropy (Daumann et al., 2003a; see
above). No signiﬁcant differences were reported.
3.4. Neurochemical imaging studies
Four included studies investigated serotonin transporter and
serotonin 5-HT2A receptor densities in moderate MDMA  users via
SPECT and PET, respectively, and one study applied FDG-PET in a
sample of polydrug users. For details and principal ﬁndings see
Table 7.
Two studies investigated densities of serotonin transporters by
measuring radioligand binding via SPECT (de Win  et al., 2008;
Reneman et al., 2001). Reneman et al. retrospectively investigated
alysed Threshold Results (user group
compared with controls, if
not indicated otherwise)
in p < 0.001, uncorrected,
cluster ≥ 20
No signiﬁcant
differencesrain, thalamus,
ortex, frontal
ipital cortex
tex, temporal
ieto-occipital
ipital cortex,
midbrain
n/p No signiﬁcant differences
tal cortex, medial
ntal cortex,
ontal cortex,
mporal cortex,
erior temporal
sory motor cortex,
rtex, occipital
otonin transporter
nin2A receptor),
atum, midbrain,
 thalamus
 transporter only)
n/p No signiﬁcant differences
in p < 0.05, uncorrected,
cluster ≥ 100 voxels
Within-group: Amount of
use: No signiﬁcant
differences
Duration of use: Left
postcentral/inferior
parietal gyrus, right
inferior frontal
gyrus/dorsolateral
prefrontal cortex, right
superior temporal pole ↓
tex p < 0.05, corrected
(FWER)
Occipital-parietal ↑,
temporal ↑,
occipitotemporal-parietal
↑, frontal ↑, frontoparietal
cortex ↑
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 sample of MDMA  users and controls. De Win  et al. prospec-
ively investigated MDMA  users with no MDMA  use at baseline. The
DMA  user group in the 2008 study showed signiﬁcantly higher
se of alcohol, cannabis, amphetamines and cocaine. No clear data
n the use of other drugs were reported by Reneman et al. and the
sers consumed more amphetamines and cocaine than controls. No
lterations in the serotonin transporter were reported in the two
tudies.
One study used PET to measure binding to serotonin 5-HT2A
eceptors (Di Iorio et al., 2012) and one study examined binding
o serotonin transporters and 5-HT2A receptors by PET (Erritzoe
t al., 2011). Di Iorio et al. reported an increase in estimated 5-
T2A receptor densities in several regions. The cumulative lifetime
ose of MDMA  was positively correlated with receptor binding
n the frontoparietal, occipitotemporal, frontolimbic and frontal
egions. Duration of abstinence had no effect on receptor binding.
he within-group analysis yielded no association to use of other
rugs, including nicotine. Erritzoe et al. found no increased recep-
or densities in their sample; the doses were considerably higher
nd time of abstinence shorter than with Di Iorio et al. Differences
etween controls and users in the use of other drugs were not
learly speciﬁed (the control group was drug-naïve expect for <15
pisodes of cannabis use, the user group had exposure to cannabis,
mphetamines, cocaine, gamma-hydroxybutyrate, and ketamine,
ut lifetime doses were not given).
Moreno-López et al. investigated a sample of polydrug users
heroin, cocaine, cannabis, alcohol, and MDMA)  recruited from an
npatient treatment centre using FDG-PET (Moreno-Lopez et al.,
012). No control group was used. The aim of the study was to
dentify speciﬁc alterations in brain metabolism induced by indi-
idual substances using correlation analysis. No correlation was
eported for the amount of MDMA  use, but the duration of MDMA
se was negatively correlated with metabolism in the left postcen-
ral/inferior parietal gyrus, right inferior frontal gyrus/dorsolateral
refrontal cortex and right superior temporal pole.
. Discussion
We  have conducted a systematic review to examine the effects
f moderate exposure to MDMA  in humans using neuroimaging
ethods. In summary, the included studies provide little, if any,
vidence for alterations induced by MDMA.  Findings could not be
eplicated in studies on similar domains. Three studies applying
tructural techniques in samples with comparable lifetime doses
f MDMA  found either no signiﬁcant results or divergent changes;
ither these were not due to MDMA  or causation by MDMA  remains
nclear, as amphetamine-type stimulants were not further differ-
ntiated. However, lifetime doses of MDMA  were small in all three
tudies, and structural changes might become apparent at higher
oses. The same holds true for fractional anisotropy deduced from
TI measurements, where one study found no alterations and two
onsecutive studies, which also investigated apparent diffusion and
elative regional blood ﬂow, reported no consistent results.
Three studies investigated serotonin transporter binding at sev-
ral lifetime doses of MDMA  and found no signiﬁcant alterations.
wo studies examined densities of serotonin 5-HT2A receptors but
eported divergent results. In a sample that exclusively included
omen, Di Iorio et al. observed increased receptor density in
arious cortical areas, which was interpreted as compensatory
pregulation due to serotonergic neurotoxicity (Di Iorio et al.,
012). However, these ﬁndings were not reproduced by another
tudy (Erritzoe et al., 2011). It seems unlikely that the described
ncrease in receptor density is due to the use of other drugs as,
n the study of Di Iorio et al., the user group only showed sig-
iﬁcantly higher use of psilocybin, which, as a serotonin agonist,havioral Reviews 62 (2016) 21–34 31
would presumably cause receptor downregulation, if anything. As
there is evidence that the effects of MDMA  are more pronounced
in women  (Liechti et al., 2001) and the population in Erritzoe et al.
consisted mostly of men, it can be speculated that women might
also be more vulnerable to neurotoxic effects. However, cumula-
tive lifetime dose was  more than three times higher in the sample
used by Erritzoe et al. and it is thus questionable whether gender
might fully explain these differences.
Four studies investigated working memory by fMRI. With a
small cumulative lifetime dose of MDMA  and a conservative sta-
tistical threshold, Jager et al. found no signiﬁcant alterations (Jager
et al., 2007). Jacobsen et al. and Daumann et al. reported several
divergent results in their studies with considerably higher doses
and liberal thresholds (Daumann et al., 2003a,b; Jacobsen et al.,
2004). These divergent results might thus be due to different doses
or different statistical thresholds and resulting type I or II errors.
Additionally, except for Jager et al., the studies are imprecise about
the use of other drugs in their populations and none fully accounts
for the use of illicit and legal drugs, which makes interpretation of
these results even more difﬁcult.
Associative memory was  investigated in two  fMRI studies by
Becker et al. and Jager et al. (Becker et al., 2013; Jager et al., 2007).
While Jager et al. reported no signiﬁcant ﬁndings and Becker et al.
found decreased activity in the left parahippocampal gyrus at a
higher lifetime dose of MDMA  in their population, the reason for
these ﬁndings remains unclear, as some differences between user
groups and controls were present at baseline.
Five studies examined decision-making, different aspects of
motor function, visual stimulation and brain metabolism. One of
these studies focused on amphetamine-type stimulants in general
and did not differentiate MDMA  (Koester et al., 2013). Another
study did not account for the signiﬁcant consumption of cocaine
in the MDMA  user group (Salomon et al., 2012). So once again, cau-
sation by MDMA  remains unclear in these reports. After adjusting
for different scanners and stimulus delivery methods, Bauern-
feind et al. reported a positive correlation between lifetime use
of MDMA  and the BOLD signal in the lateral geniculate nucleus in
their within-group analysis but no differences were found in the
between-group analysis (Bauernfeind et al., 2011). Karageorgiou
et al. (motor function by fMRI) and Moreno-López et al. (FDG-PET)
reported several results that were not corrected for by multiple
comparisons (Karageorgiou et al., 2009; Moreno-Lopez et al., 2012).
Results of these studies should thus be replicated by (ROI) analysis
using more conservative thresholds.
4.1. Effects of co-consumption of various drugs
MDMA  users are typically polydrug users, with alcohol, tobacco,
cannabis and other stimulants being the most common substances
(Wu  et al., 2009). Alcohol and nicotine are often neglected in the
analyses and the use of cannabis is not excluded for pragmatic
reasons. These confounders might have a considerable inﬂuence
on the results, as all of these substances may  cause both struc-
tural and functional changes (Carvalho et al., 2012; Martín-Santos
et al., 2010; Mechtcheriakov et al., 2007; Pan et al., 2013) and sub-
acute effects of cannabis can bias functional results (Bossong et al.,
2014). Co-consumption of other substances may  increase adverse
effects caused by MDMA,  as the use of other drugs, such as nicotine,
alcohol, cocaine and other amphetamines, may  lead to pharma-
cological interactions and additive effects (Carvalho et al., 2012).
These effects can also be protective, as cannabis may  antagonise
(Morley et al., 2004; Tourin˜o et al., 2010) the hyperthermic effects
of MDMA  (Freedman et al., 2005), which are supposed to increase
MDMA’s neurotoxicity (Capela et al., 2009).
In general, there is considerable uncertainty about the extent of
use and potential inﬂuence of other drugs in the studies discussed
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n this review. Three studies explicitly investigated effects of
mphetamine-type stimulants and not of MDMA  (Daumann et al.,
011; Koester et al., 2012, 2013). We  included these studies because
hey provided data about lifetime use of MDMA  but, due to the
esign, no attempt was made to disentangle the effects of different
mphetamines. Therefore the results of these studies provide only
imited information about the speciﬁc focus of this review. A fourth
tudy investigated the use of amphetamine-type substances and
ocaine in a population with very moderate use of MDMA  and
he authors noted that MDMA  was probably not the cause of the
bserved effects (Mackey et al., 2014). Of the remaining studies,
nly two studies provided a control group that was  matched for
se of illicit or legal drugs (Table 4). Seven studies found signiﬁcant
ifferences between user groups and controls in co-consumptions
f illicit drugs and two studies reported signiﬁcant differences in
he use of legal drugs. All but one of those studies tried to account
or these confounders in some way. Eight studies provided no
lear data about differences in the use of illicit drugs between
ontrols and user groups and seven provided no clear data about
he use of legal drugs. We  tried to calculate these missing values
nd found signiﬁcant use of cannabis in three of those studies,
hile the others did not provide enough data for calculation. Of
he 15 studies which reported any signiﬁcant result, seven failed
o provide any clear identiﬁcation of differences in the use of illicit
r legal drugs, nor did they account for these confounders in their
nalysis, which leaves some uncertainty regarding interpretation.
.2. Methodological issues
All included studies use observational designs and therefore suf-
er from a high risk for bias and confounding. Participants were
ecruited by advertisements or by word of mouth and were thus
elf-selected, not randomised members of a particular subpopu-
ation, and may  have exhibited a variety of possible pre-existing
ifferences, such as a tendency for sensation seeking and a spe-
ial “life style”. Consequently, these pre-existing factors may  be
eﬂected in neuroimaging as has already been shown for struc-
ural alterations in users of amphetamine-type stimulants with
scalating consumption patterns (Becker et al., 2015). This is also
ell illustrated in one of the studies included in this review on
ecision-making in amphetamine-type stimulants users (Koester
t al., 2013). As the authors note, it is hard to tell whether risky
ecision-making should be regarded as a cause or a consequence
f stimulant use. Prospective studies can overcome some of these
roblems; however, only four studies included in the review used
 prospective design (Becker et al., 2013; de Win  et al., 2008,
007; Jager et al., 2007). Furthermore, there is inherent uncer-
ainty about the substances actually ingested as “MDMA” as well
s the dose, as researchers have to rely on self-reported histo-
ies of drug use and the true doses are unknown in a naturalistic
nvironment. Drugs that are sold as MDMA  or “ecstasy” contain
arying amounts of MDMA,  may  contain precursors or interme-
iates (Palhol et al., 2002), and may  additionally or exclusively
ontain other psychoactive compounds with (unkown) neurotoxic
ffects, such as other amphetamines or novel psychoactive sub-
tances (Brunt et al., 2012; Giraudon and Bello, 2007; Vogels et al.,
009). By default, studies in this ﬁeld report dosages as a cumulative
ifetime dose. With respect to toxicity, dosages taken per occasion
ay  be even more important (Fox et al., 2001) than lifetime dose.
s Cole et al. remark, “if MDMA-induced neurotoxicity relied sim-
ly upon such a ‘cumulative dose’ then all patients prescribed the
eurotoxic amphetamine fenﬂuramine on a daily basis should be
xhibiting serotonergic neurotoxicity” (Cole et al., 2002). MDMA
sers often ingest more than one tablet per occasion. However,
nly three studies reported data about maximal doses per occa-
ion and this information is usually not taken into account. As heavyhavioral Reviews 62 (2016) 21–34
users are more likely to show excessive use patterns, this might also
explain some ﬁndings on neurotoxicity obtained in neuroimaging
studies in this group. Additionally, heavy users are also more likely
to show higher use of other drugs and several environmental and
lifestyle factors might be accentuated. Use of higher doses of MDMA
per occasion, effects of and interactions with other drugs, as well as
other factors might lead to increased hyperthermia and oxidative
stress, factors that are thought to cause neurotoxicity associated
with MDMA  (Carvalho et al., 2012).
5. Conclusions
In summary, studies in this ﬁeld exhibit a variety of differences
and report highly heterogeneous results. Additionally, they suffer
from problems that are inherent to the observational designs or
due to other reasons. While some problems, like imprecise data on
actual consumed doses, are unlikely to be solved, others should be
carefully accounted for, for example appropriately matched con-
trol groups, including the consumption of the legal drugs nicotine
and alcohol; moreover, such controls might be difﬁcult to recruit. In
the moderate dose range investigated in this review, we found no
clear evidence from neuroimaging techniques that MDMA  induces
changes in the human brain. This also implies that there is cur-
rently no clear evidence from neuroimaging that the use of MDMA
as an additive in psychotherapy should be regarded as dangerous
per se. On the other hand, our systematic review does not allow the
conclusion that MDMA  is not neurotoxic in moderate use, as possi-
ble alterations caused by MDMA  might not be detectable with the
techniques used, some of the included studies were not speciﬁcally
designed to investigate neurotoxic effects of MDMA  in moderate
users and several studies were of rather poor quality.
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